Skip to content
NewsBlazeIN – Lifestyle
Author:
Clywedog Therapeutics, Inc.
Clywedog Therapeutics Announces Final Results from a Phase 1b Study of Balomenib in Type 2 Diabetes Patients, Showing Glycemic Improvement Sustained for Three Months After a Three-Week Course of Treatment
September 24, 2026